Role of Angiogenesis in the Pathogenesis of NAFLD
Abstract
1. Introduction
2. Evidence of Angiogenesis in NAFLD
2.1. In Animal Models
2.2. In Patients
3. Role of Angiogenesis in the Progression of NAFLD
4. Angiogenesis as a Potential Therapeutic Target in NAFLD
Author Contributions
Funding
Conflicts of Interest
Abbreviations
Ang-2 | Angiopoietin-2 |
CDAA | Choline-Deficient Amino Acid |
HCC | Hepatocellular Carcinoma |
HFD | High-Fat Diet |
HIF | Hypoxia-Inducible Factor |
LSEC | Liver Sinusoidal Endothelial Cell |
MCD | Methionine- and Choline-Deficient |
NAFL | Non-Alcoholic Fatty Liver |
NAFLD | Non-Alcoholic Fatty Liver Disease |
NASH | Non-Alcoholic Steatohepatitis |
PDGF | Platelet-Derived Growth Factor |
PlGF | Placenta Growth Factor |
STZ | Streptozotocin |
TGF-ß | Transforming Growth Factor-ß |
VCAM-1 | Vascular Cell Adhesion Molecule-1 |
VEGF | Vascular Endothelial Growth Factor |
sVEGFR | Soluble Vascular Endothelial Growth Factor Receptor |
References
- Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. [Google Scholar] [CrossRef]
- Gordan, J.D.; Kennedy, E.B.; Abou-Alfa, G.K.; Beg, M.S.; Brower, S.T.; Gade, T.P.; Goff, L.; Gupta, S.; Guy, J.; Harris, W.P.; et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J. Clin. Oncol. 2020, 38, 4317–4345. [Google Scholar] [CrossRef] [PubMed]
- Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nat. Cell Biol. 2011, 473, 298–307. [Google Scholar] [CrossRef] [PubMed]
- Coulon, S.; Heindryckx, F.; Geerts, A.; Van Steenkiste, C.; Colle, I.; Van Vlierberghe, H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2010, 31, 146–162. [Google Scholar] [CrossRef] [PubMed]
- Zadorozhna, M.; Di Gioia, S.; Conese, M.; Mangieri, D. Neovascularization is a key feature of liver fibrosis progression: Anti-angiogenesis as an innovative way of liver fibrosis treatment. Mol. Biol. Rep. 2020, 47, 2279–2288. [Google Scholar] [CrossRef]
- Lemoinne, S.; Thabut, M.; Housset, C. Portal myofibroblasts connect angiogenesis and fibrosis in liver. Cell Tissue Res. 2016, 365, 583–589. [Google Scholar] [CrossRef]
- Poisson, J.; Lemoinne, S.; Boulanger, C.; Durand, F.; Moreau, R.; Valla, D.; Rautou, P.-E. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J. Hepatol. 2017, 66, 212–227. [Google Scholar] [CrossRef] [PubMed]
- Kumar, P.; Wang, J.M.; Bernabeu, C. CD 105 and angiogenesis. J. Pathol. 1996, 178, 363–366. [Google Scholar] [CrossRef]
- Jahn, D.; Kircher, S.; Hermanns, H.M.; Geier, A. Animal models of NAFLD from a hepatologist’s point of view. Biochim. Biophys. Acta Mol. Basis Dis. 2019, 1865, 943–953. [Google Scholar] [CrossRef]
- Plaza, A.; Naranjo, V.; Blonda, A.M.; Cano, V.; González-Martín, C.; Gil-Ortega, M.; Ruiz-Gayo, M.; Merino, B. Inflammatory stress and altered angiogenesis evoked by very high-fat diets in mouse liver. Endocrinol. Diabetes Nutr. 2019, 66, 434–442. [Google Scholar] [CrossRef]
- Kitade, M.; Yoshiji, H.; Kojima, H.; Ikenaka, Y.; Noguchi, R.; Kaji, K.; Yoshii, J.; Yanase, K.; Namisaki, T.; Asada, K.; et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44, 983–991. [Google Scholar] [CrossRef] [PubMed]
- Coulon, S.; Legry, V.; Heindryckx, F.; Van Steenkiste, C.; Casteleyn, C.; Olievier, K.; Libbrecht, L.; Carmeliet, P.; Jonckx, B.; Stassen, J.-M.; et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 2013, 57, 1793–1805. [Google Scholar] [CrossRef]
- Lefere, S.; Van De Velde, F.; Hoorens, A.; Raevens, S.; Van Campenhout, S.; Vandierendonck, A.; Neyt, S.; Vandeghinste, B.; Vanhove, C.; Debbaut, C.; et al. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology 2019, 69, 1087–1104. [Google Scholar] [CrossRef]
- Lemoinne, S.; Cadoret, A.; Rautou, P.; El Mourabit, H.; Ratziu, V.; Corpechot, C.; Rey, C.; Bosselut, N.; Barbu, V.; Wendum, D.; et al. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology 2015, 61, 1041–1055. [Google Scholar] [CrossRef] [PubMed]
- Kitade, M.; Yoshiji, H.; Kojima, H.; Ikenaka, Y.; Noguchi, R.; Kaji, K.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; et al. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. Mol. Med. Rep. 2008, 1, 543–548. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Coulon, S.; Francque, S.; Colle, I.; Verrijken, A.; Blomme, B.; Heindryckx, F.; De Munter, S.; Prawitt, J.; Caron, S.; Staels, B.; et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012, 59, 442–449. [Google Scholar] [CrossRef] [PubMed]
- Lefere, S.; Van De Velde, F.; Devisscher, L.; Bekaert, M.; Raevens, S.; Verhelst, X.; Van Nieuwenhove, Y.; Praet, M.; Hoorens, A.; Van Steenkiste, C.; et al. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int. J. Obes. 2017, 41, 1207–1213. [Google Scholar] [CrossRef]
- Lefere, S.; Devisscher, L.; Geerts, A. Angiogenesis in the progression of non-alcoholic fatty liver disease. Acta Gastroenterol. Belg. 2020, 83, 301–307. [Google Scholar]
- Farrell, G.C.; Teoh, N.; McCuskey, R. Hepatic Microcirculation in Fatty Liver Disease. Anat. Rec. Adv. Integr. Anat. Evol. Biol. 2008, 291, 684–692. [Google Scholar] [CrossRef]
- Baffy, G. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Dig. Dis. Sci. 2018, 63, 563–576. [Google Scholar] [CrossRef]
- Miura, K.; Ohnishi, H.; Morimoto, N.; Minami, S.; Ishioka, M.; Watanabe, S.; Tsukui, M.; Takaoka, Y.; Nomoto, H.; Isoda, N.; et al. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Cancer Sci. 2018, 110, 771–783. [Google Scholar] [CrossRef]
- Hammoutene, A.; Rautou, P.-E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J. Hepatol. 2019, 70, 1278–1291. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, F.J.; Xie, C.; Jiang, C. The role of hypoxia-inducible factors in metabolic diseases. Nat. Rev. Endocrinol. 2019, 15, 21–32. [Google Scholar] [CrossRef] [PubMed]
- Khazaei, M.; Tahergorabi, Z. Leptin and its cardiovascular effects: Focus on angiogenesis. Adv. Biomed. Res. 2015, 4, 79. [Google Scholar] [CrossRef] [PubMed]
- Dewidar, B.; Meyer, C.; Dooley, S.; Meindl-Beinker, N. TGF-beta in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells 2019, 8, 1419. [Google Scholar] [CrossRef] [PubMed]
- Van Meeteren, L.A.; Goumans, M.J.; ten Dijke, P. TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr. Pharm. Biotechnol. 2011, 12, 2108–2120. [Google Scholar] [CrossRef] [PubMed]
- Das, S.K.; Balakrishnan, V. Role of Cytokines in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Indian J. Clin. Biochem. 2011, 26, 202–209. [Google Scholar] [CrossRef]
- Hasegawa, T.; Yoneda, M.; Nakamura, K.; Makino, I.; Terano, A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol. Ther. 2001, 15, 1667–1672. [Google Scholar] [CrossRef] [PubMed]
- Granzow, M.; Schierwagen, R.; Klein, S.; Kowallick, B.; Huss, S.; Linhart, M.; Mazar, I.G.R.; Görtzen, J.; Vogt, A.; Schildberg, F.A.; et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014, 60, 334–348. [Google Scholar] [CrossRef]
- Morris, E.M.; Fletcher, J.A.; Thyfault, J.P.; Rector, R.S. The role of angiotensin II in nonalcoholic steatohepatitis. Mol. Cell Endocrinol. 2013, 378, 29–40. [Google Scholar] [CrossRef]
- Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Asada, K. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol. Res. 2006, 36, 124–129. [Google Scholar] [CrossRef] [PubMed]
- Lefere, S.; Tacke, F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 2019, 1, 30–43. [Google Scholar] [CrossRef]
- Ramachandran, P.; Dobie, R.; Wilson-Kanamori, J.R.; Dora, E.F.; Henderson, B.E.P.; Luu, N.T.; Portman, J.R.; Matchett, K.P.; Brice, M.; Marwick, J.A.; et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nat. Cell Biol. 2019, 575, 512–518. [Google Scholar] [CrossRef]
- Krenkel, O.; Puengel, T.; Govaere, O.; Abdallah, A.T.; Mossanen, J.C.; Kohlhepp, M.; Liepelt, A.; Lefebvre, E.; Luedde, T.; Hellerbrand, C.; et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018, 67, 1270–1283. [Google Scholar] [CrossRef]
- Ehling, J.; Bartneck, M.; Wei, X.; Gremse, F.; Fech, V.; Möckel, D.; Baeck, C.; Hittatiya, K.; Eulberg, D.; Luedde, T.; et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014, 63, 1960–1971. [Google Scholar] [CrossRef]
- Van der Pol, E.; Böing, A.N.; Harrison, P.; Sturk, A.; Nieuwland, R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 2012, 64, 676–705. [Google Scholar] [CrossRef] [PubMed]
- Todorova, D.; Simoncini, S.; Lacroix, R.; Sabatier, F.; Dignat-George, F. Extracellular Vesicles in Angiogenesis. Circ. Res. 2017, 120, 1658–1673. [Google Scholar] [CrossRef]
- Lemoinne, S.; Thabut, D.; Housset, C.; Moreau, R.; Valla, D.; Boulanger, C.M.; Rautou, P.-E. The emerging roles of microvesicles in liver diseases. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 350–361. [Google Scholar] [CrossRef]
- Szabo, G.; Momen-Heravi, F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 455–466. [Google Scholar] [CrossRef] [PubMed]
- Povero, D.; Eguchi, A.; Niesman, I.R.; Andronikou, N.; Jeu, X.D.M.D.; Mulya, A.; Berk, M.; Lazic, M.; Thapaliya, S.; Parola, M.; et al. Lipid-Induced Toxicity Stimulates Hepatocytes to Release Angiogenic Microparticles That Require Vanin-1 for Uptake by Endothelial Cells. Sci. Signal. 2013, 6, ra88. [Google Scholar] [CrossRef]
- Stine, J.G.; Wentworth, B.J.; Zimmet, A.; Rinella, M.E.; Loomba, R.; Caldwell, S.H.; Argo, C.K. Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment. Pharmacol. Ther. 2018, 48, 696–703. [Google Scholar] [CrossRef] [PubMed]
- Villa, E.; Critelli, R.; Lei, B.; Marzocchi, G.; Cammà, C.; Giannelli, G.; Pontisso, P.; Cabibbo, G.; Enea, M.; Colopi, S.; et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 2016, 65, 861–869. [Google Scholar] [CrossRef]
- Corpechot, C.; Barbu, V.; Wendum, D.; Kinnman, N.; Rey, C.; Poupon, R.; Housset, C.; Rosmorduc, O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35, 1010–1021. [Google Scholar] [CrossRef] [PubMed]
- Novo, E.; Povero, D.; Busletta, C.; Paternostro, C.; Di Bonzo, L.V.; Cannito, S.; Compagnone, A.; Bandino, A.; Marra, F.; Colombatto, S.; et al. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J. Pathol. 2011, 226, 588–597. [Google Scholar] [CrossRef]
- Van Steenkiste, C.; Ribera, J.; Geerts, A.; Pauta, M.; Tugues, S.; Casteleyn, C.; Libbrecht, L.; Olievier, K.; Schroyen, B.; Reynaert, H.; et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011, 53, 1629–1640. [Google Scholar] [CrossRef] [PubMed]
- Tamaki, Y.; Nakade, Y.; Yamauchi, T.; Makino, Y.; Yokohama, S.; Okada, M.; Aso, K.; Kanamori, H.; Ohashi, T.; Sato, K.; et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J. Gastroenterol. 2013, 48, 491–503. [Google Scholar] [CrossRef] [PubMed]
- Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D.J.; Wu, Y.; Yanase, K.; Namisaki, T.; Yamazaki, M.; et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52, 1347–1354. [Google Scholar] [CrossRef]
- Tugues, S.; Fernandez-Varo, G.; Muñoz-Luque, J.; Ros, J.; Arroyo, V.; Rodés, J.; Friedman, S.L.; Carmeliet, P.; Jiménez, W.; Morales-Ruiz, M. Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007, 46, 1919–1926. [Google Scholar] [CrossRef]
- Taura, K.; De Minicis, S.; Seki, E.; Hatano, E.; Iwaisako, K.; Osterreicher, C.H.; Kodama, Y.; Miura, K.; Ikai, I.; Uemoto, S.; et al. Hepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis. Gastroenterology 2008, 135, 1729–1738. [Google Scholar] [CrossRef]
- Mejias, M.; Garcia-Pras, E.; Tiani, C.; Miquel, R.; Bosch, J.; Fernandez, M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2008, 49, 1245–1256. [Google Scholar] [CrossRef]
- Thabut, D.; Routray, C.; Lomberk, G.; Shergill, U.; Glaser, K.; Huebert, R.; Patel, L.; Masyuk, T.; Blechacz, B.; Vercnocke, A.; et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011, 54, 573–585. [Google Scholar] [CrossRef]
- Hennenberg, M.; Trebicka, J.; Kohistani, Z.; Stark, C.; Nischalke, H.-D.; Krämer, B.; Körner, C.; Klein, S.; Granzow, M.; Fischer, H.-P.; et al. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab. Investig. 2010, 91, 241–251. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.; Feng, H.; Kan, T.; Huang, B.; Zhang, M.; Li, Y.; Shi, C.; Wu, M.; Luo, Y.; Yang, J.; et al. Bevacizumab Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells. PLoS ONE 2013, 8, e73492. [Google Scholar] [CrossRef]
- Yang, L.; Kwon, J.; Popov, Y.; Gajdos, G.B.; Ordog, T.; Brekken, R.A.; Mukhopadhyay, D.; Schuppan, D.; Bi, Y.; Simonetto, D.; et al. Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. Gastroenterology 2014, 146, 1339–1350.e1. [Google Scholar] [CrossRef]
Model | Steatosis | NASH | Fibrosis | HCC | Description of Liver Angiogenesis | Reference |
---|---|---|---|---|---|---|
HFD mouse | +++ | + | + | absent | Increase of CD31, VEGFR-2 | [10] |
MCD mouse | +++ | +++ | + | absent | Increase of vWF, CD105, VEGF, Ang-2 Increase of vascular density | [12] |
CDAA rat | +++ | +++ | +++ | present | Increase of CD31, VEGF | [11] |
STZ + Western diet mouse | +++ | +++ | ++ | present | Increase of Ang-2 Increase of vascular density | [13] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lei, L.; EI Mourabit, H.; Housset, C.; Cadoret, A.; Lemoinne, S. Role of Angiogenesis in the Pathogenesis of NAFLD. J. Clin. Med. 2021, 10, 1338. https://doi.org/10.3390/jcm10071338
Lei L, EI Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of Angiogenesis in the Pathogenesis of NAFLD. Journal of Clinical Medicine. 2021; 10(7):1338. https://doi.org/10.3390/jcm10071338
Chicago/Turabian StyleLei, Lin, Haquima EI Mourabit, Chantal Housset, Axelle Cadoret, and Sara Lemoinne. 2021. "Role of Angiogenesis in the Pathogenesis of NAFLD" Journal of Clinical Medicine 10, no. 7: 1338. https://doi.org/10.3390/jcm10071338
APA StyleLei, L., EI Mourabit, H., Housset, C., Cadoret, A., & Lemoinne, S. (2021). Role of Angiogenesis in the Pathogenesis of NAFLD. Journal of Clinical Medicine, 10(7), 1338. https://doi.org/10.3390/jcm10071338